Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the Knee

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02845271
Recruitment Status : Completed
First Posted : July 27, 2016
Last Update Posted : September 29, 2017
Sponsor:
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )

Brief Summary:

Primary Objective:

To assess the efficacy of a single intraarticular dose of GZ389988 compared to placebo for relief of knee pain in patients with osteoarthritis (OA) of the knee.

Secondary Objectives:

To assess the safety and tolerability of a single intraarticular dose of GZ389988 in patients with painful OA of the knee.

To assess the pharmacokinetic parameters of a single intraarticular dose of GZ389988 in patients with painful OA of the knee.


Condition or disease Intervention/treatment Phase
Osteoarthritis Drug: placebo Drug: GZ389988 Drug: acetaminophen or paracetamol Drug: fixed combination of paracetamol + codeine Drug: fixed combination of paracetamol + tramadol hydrochloride Phase 2

Detailed Description:

Screening will be performed within 21 days of dosing. Following the single dose of study medication, the study period for each patient will be 84 ± 7 days up to the end-of-study visit.

Total duration for one patient will be up to 16 weeks (up to the end-of-study visit), not including the long-term observational safety follow-up phone call for 12 additional weeks.

The collection of primary endpoint data up to Week 4 for futility analysis is optional. Assuming a possible step-down in dose due to safety/tolerability reasons, the total expected maximum number of included patients could be increased up to a maximum of 182 patients.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 104 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Two Part Protocol Using Double Blind Placebo Control to Assess the Safety, Tolerability, and Pharmacokinetics of Single Escalating Intra-articular Doses Followed by Assessment of Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Intra-articular Dose of the TrkA Inhibitor, GZ389988, in Patients With Painful Osteoarthritis of the Knee
Actual Study Start Date : July 21, 2016
Actual Primary Completion Date : June 28, 2017
Actual Study Completion Date : September 13, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: GZ389988
Single intraarticular injection of GZ389988 in the knee joint
Drug: GZ389988

Pharmaceutical form:suspension for injection

Route of administration: intraarticular


Drug: acetaminophen or paracetamol

Pharmaceutical form: tablet

Route of administration: oral


Drug: fixed combination of paracetamol + codeine

Pharmaceutical form: capsule

Route of administration: oral


Drug: fixed combination of paracetamol + tramadol hydrochloride

Pharmaceutical form: tablet

Route of administration: oral


Placebo Comparator: Placebo
Single intraarticular injection of placebo for GZ389988 in the knee joint
Drug: placebo

Pharmaceutical form:solvent for parenteral use

Route of administration: intraarticular


Drug: acetaminophen or paracetamol

Pharmaceutical form: tablet

Route of administration: oral


Drug: fixed combination of paracetamol + codeine

Pharmaceutical form: capsule

Route of administration: oral


Drug: fixed combination of paracetamol + tramadol hydrochloride

Pharmaceutical form: tablet

Route of administration: oral





Primary Outcome Measures :
  1. Change from baseline in weekly mean score of Western Ontario and McMaster Universities Arthritis Index (WOMAC) A1 pain subscore (walking pain) collected daily in the target knee, as measured by the Visual Analogue Scale (VAS) 0-100 [ Time Frame: Averaged over 4 weeks (up to Day 28) ]

Secondary Outcome Measures :
  1. Change from baseline in weekly mean score of WOMAC A1 pain sub-score (walking pain) collected daily in the target knee, as measured by the VAS 0-100 [ Time Frame: Averaged over 12 weeks (up to Day 84) ]
  2. Change from baseline in weekly mean score of WOMAC A1 pain sub-score collected daily in the target knee [ Time Frame: Averaged over 1, 2, 3, 6, 8, and 10 weeks ]
  3. Change from baseline in weekly mean score of WOMAC A1 pain sub-score collected daily in the target knee [ Time Frame: At 1, 2, 3, 4, 6, 8, 10, and 12 weeks ]
  4. Change from baseline in weekly mean score of overall knee pain collected daily in the target knee [ Time Frame: At and averaged over 1, 2, 3, 4, 6, 8, 10, and 12 weeks ]
  5. Change from baseline in Patient Global Assessment (PGA) of disease status [ Time Frame: At and averaged over 1, 2, 3, 4, 6, 8, 10, and 12 weeks ]
  6. Change from baseline in WOMAC index (total score for pain, stiffness, and physical function subscales), pain, stiffness and physical function sub-scores [ Time Frame: Averaged over 1, 2, 3, 4, 6, 8, 10, and 12 weeks ]
  7. Patient Global Impression of Change (PGIC) [ Time Frame: Over the last 4 weeks at Day 28 (1 to 4 weeks), Day 56 (5 to 8 weeks), and Day 84 (9 to 12 weeks) ]
  8. Patient Global Assessment of Response to Therapy (PGART) [ Time Frame: Over the last 4 weeks at Day 28 (1 to 4 weeks), Day 56 (5 to 8 weeks), and Day 84 (9 to 12 weeks) ]
  9. Rate of response to therapy according to Outcome Measures in Rheumatology committee (OMERACT) and the Osteoarthritis Research Society International (OARSI) [ Time Frame: By Day 28, Day 56, and Day 84 ]
    OMERACT and OARSI responder criteria are based on the symptomatic variables pain and function, or pain, function and patient's global assessment

  10. WOMAC A1 responder rate based on percentage of patients with reduction in pain intensity of at least 30% and 50% at endpoint compared to baseline [ Time Frame: Over 4 weeks (up to Day 28) and 12 weeks (up to Day 84) and at 1, 2, 3, 4, 6, 8, 10, and 12 weeks ]
  11. Time to first WOMAC A1 response for ≥30% reduction in pain intensity [ Time Frame: At 1, 2, 3, 4, 6, 8, 10, 12 weeks ]
  12. Time to first WOMAC A1 response for 50% reduction in pain intensity [ Time Frame: At 1, 2, 3, 4, 6, 8, 10, 12 weeks ]
  13. Amount of rescue medication intake [ Time Frame: Up to Day 84 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria :

  • Men or women 40 to 80 years of age.
  • Diagnosis of primary knee osteoarthritis (OA), based upon the following:
  • Fulfilling the American College of Rheumatology Clinical and Radiographic criteria for OA (at least knee pain and osteophytes), with
  • X-ray evidence within the last 6 months for Kellgren and Lawrence classification II to IV.
  • Western Ontario and McMaster Universities Arthritis Index (WOMAC) A1 Pain subscore (walking pain) over the last 48 hours ≥40 and ≤90 on VAS 0-100 in the target knee at screening with or without medication, and ≤30 on Visual Analogue Scale (VAS) 0-100 in the contralateral knee at screening with or without medication.
  • WOMAC A1 pain subscore (walking pain) between 50 and 90 using the VAS 0-100, corresponding to moderate to severe pain in the target knee at baseline (from eDiary, average of at least 3 days in the time window between Day-5 and Day-1).
  • Symptomatic for more than 6 months (if both symptomatic knees, at least for the most painful knee that will receive the study drug).
  • Having given written informed consent prior to any procedure related to the study.
  • Ambulatory with an active lifestyle and in good general health. (Assistive devices were allowed if used throughout a period of 3 months or more prior to screening, on the condition that they continue to be used throughout the study).
  • A male who is sexually active must use a condom as part of a method of highly effective contraception (eg, condom + spermicide, and an additional contraceptive method used by the partner) during sexual intercourse with a women of childbearing potential for the duration of the study period up to the end-of-study visit and should not father a child in this period. Male patients also have to agree not to donate sperm for the duration of the study until the end-of-study visit.

Exclusion criteria:

  • Women of childbearing potential.
  • Pregnant or breastfeeding women.
  • Any uncontrolled, chronic condition or laboratory finding which, in the opinion of the Investigator, could potentially put the patient at increased risk.
  • Patients with clinically significant or uncontrolled hepatic, gastrointestinal, cardiovascular, respiratory, neurological (including diabetic neuropathy), psychiatric, hematological, renal, or dermatological disease, or any other medical condition, such as symptomatic peripheral vascular disease of the study leg (prior or current), clinically significant venous or lymphatic stasis present in the study leg, that might interfere with the evaluation of investigational medicinal product (IMP) according to Investigator's medical judgment.
  • Chondrocalcinosis.
  • Fibromyalgia.
  • Moderately severe or severe depression as indicated by Patient Health Questionnaire-9 (PHQ-9) total score at screening visit.
  • Severe anxiety as indicated by Generalized Anxiety Disorder (GAD-7) score at screening visit.
  • History or presence of drug or alcohol abuse (alcohol consumption >40 grams per day).
  • Any patient who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development, or unable to use an electronic diary daily.
  • Abnormal coagulation parameters: outside the range international normalized ratio (INR) 0.85-1.15, activated partial thromboplastin time >33 seconds, platelets <140 x 10^9/L.
  • Moderate to severe renal impairment.
  • Underlying hepatobiliary disease and/or alanine aminotransferase (ALT) >2 x upper limit of normal (ULN).
  • High sensitivity C-reactive protein (hsCRP) >2 x ULN.
  • Hemoglobin <10 g/dL, white blood cell count (WBC) <3 x 10^9/L.
  • Positive result on any of the following tests: hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab).
  • Secondary OA. -Ipsilateral hip OA.-
  • History of osteonecrosis and/or rapidly progressive OA (RPOA).
  • Intraarticular injection within 3 months prior to inclusion.
  • Unable to be maintained for at least 2 weeks prior to entry into study on paracetamol (no non-steroidal anti-inflammatory drug [NSAID] use during the 12 weeks of the study; after the end-of-study visit [Day 84 ± 7] patients may be given an NSAID if necessary to provide better control of OA symptoms).
  • Any IMP within 3 months prior to the study.
  • Any knee magnetic resonance imaging (MRI) contraindication.
  • Patients at risk of developing a RPOA with pre-existing findings on MRI of the target knee at baseline.
  • Patients with pain DETECT questionnaire (PD-Q) score >18.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02845271


Locations
Layout table for location information
Germany
Investigational Site Number 276001
Berlin, Germany, 14050
Investigational Site Number 276002
Luebeck, Germany, 23538
Sponsors and Collaborators
Genzyme, a Sanofi Company
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Genzyme, a Sanofi Company
ClinicalTrials.gov Identifier: NCT02845271     History of Changes
Other Study ID Numbers: ACT13830
2014-004805-34 ( EudraCT Number )
U1111-1163-0806 ( Other Identifier: UTN )
First Posted: July 27, 2016    Key Record Dates
Last Update Posted: September 29, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com
Additional relevant MeSH terms:
Layout table for MeSH terms
Acetaminophen
Codeine
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Tramadol
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antipyretics
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Antitussive Agents
Respiratory System Agents